Korro Bio (NASDAQ:KRRO) Now Covered by Analysts at Oppenheimer

Oppenheimer began coverage on shares of Korro Bio (NASDAQ:KRRO - Free Report) in a research note published on Friday, Marketbeat.com reports. The firm issued an outperform rating and a $155.00 price objective on the stock.

KRRO has been the subject of several other research reports. Royal Bank of Canada upped their target price on shares of Korro Bio from $95.00 to $105.00 and gave the company an "outperform" rating in a research note on Monday, October 21st. Raymond James assumed coverage on Korro Bio in a research report on Monday, October 21st. They issued a "strong-buy" rating and a $153.00 target price on the stock. William Blair reissued an "outperform" rating on shares of Korro Bio in a research report on Wednesday, November 13th. Finally, HC Wainwright reissued a "buy" rating and set a $115.00 target price on shares of Korro Bio in a report on Friday, November 22nd. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $144.00.

Korro Bio Trading Down 6.3 %

KRRO stock traded down $2.36 during midday trading on Friday, hitting $35.26. 107,212 shares of the company traded hands, compared to its average volume of 94,851. The business has a 50 day simple moving average of $48.80 and a 200-day simple moving average of $45.92. Korro Bio has a twelve month low of $30.00 and a twelve month high of $98.00.

Korro Bio (NASDAQ:KRRO - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($2.26) earnings per share for the quarter, beating the consensus estimate of ($2.55) by $0.29. Equities analysts predict that Korro Bio will post -9.7 EPS for the current year.

Insider Activity

In related news, CFO Vineet Agarwal sold 800 shares of the firm's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $70.00, for a total value of $56,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 5.40% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of KRRO. Brown Brothers Harriman & Co. purchased a new position in Korro Bio during the second quarter valued at $28,000. Quest Partners LLC raised its stake in shares of Korro Bio by 172.1% in the third quarter. Quest Partners LLC now owns 1,777 shares of the company's stock worth $59,000 after buying an additional 1,124 shares during the period. Vestcor Inc purchased a new position in shares of Korro Bio during the 3rd quarter valued at about $100,000. MetLife Investment Management LLC grew its stake in shares of Korro Bio by 129.0% during the 3rd quarter. MetLife Investment Management LLC now owns 3,639 shares of the company's stock valued at $122,000 after acquiring an additional 2,050 shares during the period. Finally, Lynx1 Capital Management LP purchased a new stake in Korro Bio in the 2nd quarter worth approximately $129,000. 13.18% of the stock is owned by hedge funds and other institutional investors.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).